Loading...
Targeting HOX/PBX dimers in cancer
Morgan, Richard El-Tanani, Mohamed Hunter, K.D. Harrington, K.J. Pandha, H.S.
Morgan, Richard
El-Tanani, Mohamed
Hunter, K.D.
Harrington, K.J.
Pandha, H.S.
Publication Date
2017-03-07
End of Embargo
Supervisor
Keywords
Rights
© 2017 Morgan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2017-02-23
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
The HOX and PBX gene families encode transcription factors that have key roles
in establishing the identity of cells and tissues in early development. Over the last 20
years it has become apparent that they are also dysregulated in a wide range of solid
and haematological malignancies and have a predominantly pro-oncogenic function.
A key mode of transcriptional regulation by HOX and PBX proteins is through their
interaction as a heterodimer or larger complex that enhances their binding affinity and
specificity for DNA, and there is growing evidence that this interaction is a potential
therapeutic target in malignancies that include prostate, breast, renal, ovarian
and lung cancer, melanoma, myeloma, and acute myeloid leukaemia. This review
summarizes the roles of HOX and PBX genes in cancer and assesses the therapeutic
potential of HOX/PBX dimer inhibition, including the availability of biomarkers for its
application in precision medicine.
Version
Published version
Citation
Morgan R, El-Tanani M, Hunter KD et al (2017) Targeting HOX/PBX dimers in cancer. Oncotarget. 8(19): 32322-32331.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article